Pyridoxine (Vitamin B6) Supplementation for 12-Dose Weekly Isoniazid-Rifapentine (3HP) Regimen
Pyridoxine (vitamin B6) supplementation is not explicitly required in the FDA-approved labeling for the 12-dose weekly isoniazid-rifapentine (3HP) regimen for latent tuberculosis infection, though it remains a reasonable clinical consideration for high-risk patients.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for rifapentine (PRIFTIN) does not mandate pyridoxine supplementation for the 3HP regimen used in latent TB infection 1. The drug label specifies dosing for both adults and children receiving once-weekly isoniazid plus rifapentine for 12 weeks, but pyridoxine is notably absent from these recommendations 1.
In contrast, the same FDA label explicitly requires pyridoxine (25-50 mg daily) when rifapentine is used for active pulmonary tuberculosis treatment, where isoniazid is given daily rather than weekly 1.
Guideline Recommendations
The 2025 ATS/CDC/ERS/IDSA guidelines state that "Pyridoxine (vitamin B6), 25–50 mg/d, should be given with isoniazid to all patients" in the context of active TB treatment regimens 2. However, this recommendation appears in sections discussing daily isoniazid administration for active disease, not the weekly 3HP regimen for latent infection.
The 2018 CDC MMWR update on 3HP for latent TB infection does not include pyridoxine as part of the recommended regimen 3.
Clinical Rationale and Risk Stratification
The key distinction lies in dosing frequency and total isoniazid exposure:
- 3HP regimen: 900 mg isoniazid once weekly × 12 doses = intermittent, high-dose exposure
- Active TB regimen: 300 mg isoniazid daily × 180+ days = continuous, cumulative exposure
High-Risk Populations for Peripheral Neuropathy
While not mandated for 3HP, pyridoxine supplementation (25-50 mg daily or weekly) should be strongly considered for patients at elevated risk of isoniazid-induced peripheral neuropathy 4:
- Diabetes mellitus
- Chronic kidney disease or dialysis
- Alcohol use disorder
- Malnutrition or low body weight
- Pregnancy and breastfeeding
- HIV infection with advanced disease
- Pre-existing peripheral neuropathy
- Elderly patients (≥65 years)
Safety Profile from Clinical Studies
Large observational studies of 3HP demonstrate that peripheral neuropathy is not a commonly reported adverse event with this regimen 5, 6, 7. The most frequent adverse reactions include flu-like symptoms (38%), gastrointestinal effects (32%), and rarely hepatotoxicity (2-4%) 6. This contrasts sharply with daily isoniazid regimens where neuropathy is a well-recognized complication requiring routine pyridoxine prophylaxis 4.
Practical Clinical Approach
For standard-risk patients: Pyridoxine supplementation is optional for the 3HP regimen. Educate patients about neuropathy symptoms (numbness, tingling in extremities) and provide pyridoxine if symptoms develop.
For high-risk patients (any condition listed above): Administer pyridoxine 25-50 mg either:
- Once weekly on the same day as 3HP administration, OR
- Daily throughout the 12-week treatment course
Common pitfall: Do not assume that guidelines for daily isoniazid (9H regimen) automatically apply to weekly 3HP. The pharmacokinetics and toxicity profiles differ substantially between intermittent high-dose and daily low-dose isoniazid administration.
Monitoring Considerations
Regardless of pyridoxine use, patients on 3HP should be evaluated monthly for adverse effects 3. Baseline hepatic function testing is recommended for patients with liver disease, and pyridoxine does not prevent hepatotoxicity—the most clinically significant adverse effect of the 3HP regimen 1.
The absence of pyridoxine in FDA labeling and recent CDC guidelines for 3HP reflects the lower neuropathy risk with intermittent dosing, but clinical judgment should prevail for vulnerable populations where the minimal cost and risk of supplementation is justified 4.